On a mild day in April 2016, a Marriott Hotel conference room in Hyattsville, Md., was the scene of one of the most politically charged panel meetings the US Food and Drug Administration held in years. A throng of parents and young boys in wheelchairs hoped to convince a committee to endorse the use of a controversial drug for Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease.
Drug companies are complying with their obligation to submit clinical trial results to the US-based ClinicalTrials.gov database, but major errors in their submissions prevent the results from being uploaded in a timely manner.
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
Highlighting key late-stage drugs that could reach their first markets during 2019, including first-in-class products, medicines likely to become standards of care, and products introduced for major new indications.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.